Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate

BACKGROUND: Loss of bronchoprotection (LOBP) with a regularly used long-acting β(2)-adrenergic receptor agonist (LABA) is well documented. LOBP has been attributed to β(2)-adrenergic receptor (B2AR) downregulation, a process requiring farnesylation, which is inhibited by alendronate. OBJECTIVE: We s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Allergy Clin Immunol
Main Authors: Cardet, Juan Carlos, Jiang, Xiaofeng, Lu, Quan, Gerard, Norma, McIntire, Kristen, Boushey, Homer A., Castro, Mario, Chinchilli, Vernon M., Codispoti, Christopher D., Dyer, Anne-Marie, Holguin, Fernando, Kraft, Monica, Lazarus, Stephen, Lemanske, Robert F., Lugogo, Njira, Mauger, Dave, Moore, Wendy C., Moy, James, Ortega, Victor E., Peters, Stephen P., Smith, Lewis J., Solway, Julian, Sorkness, Christine A., Sumino, Kaharu, Wechsler, Michael E., Wenzel, Sally, Israel, Elliot
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6950766/
https://ncbi.nlm.nih.gov/pubmed/30872116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2019.01.049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados